Stocks fall flat after coronavirus trial fails

WALL Street finished almost unchanged, giving up earlier gains after a trial for a COVID-19 treatment appeared to fail.

Stocks fall flat after coronavirus trial fails Stocks fall flat after coronavirus trial fails Stocks fall flat after coronavirus trial fails Stocks fall flat after coronavirus trial fails Stocks fall flat after coronavirus trial fails

According to the Financial Times, 13.9% of patients being treated with Gilead Sciences' drug remdesivir died, versus 12.8% receiving standard care.

Initial jobless claims for last week were 4.

topics

loader